Company intelligence / Profile preview

NeuRX Health

Warwick, Rhode Island, United States

Ownership: Public · ODYS
Development stage: Other

Overview

NeuRX Health recently acquired global manufacturing and distribution rights for BreastCheck™, a non-invasive, rapid home test for breast anomalies including breast cancer. The device is registered and approved (Class 1 Medical Device; FDA, CE, UKCA) and is set for international commercial launch in 2024[3].

Therapeutic areas: Oncology
Modalities: Device
Industry: Physiological Monitoring

Partnerships

Davion Healthcare

Financials

Market cap: $58.7M
Total revenue: $420K
Enterprise value: $42M

Beyond the preview

Go deeper on NeuRX Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuRX Health.

Explore the full profile